Tixagevimab and cilgavimab are two recombinant human IgG1 monoclonal antibodies with amino acid substitutions to extend antibody half-life (YTE), reduce antibody effector function, and minimize the potential risk of antibody-dependent enhancement of disease (TM). Tixagevimab and cilgavimab can simultaneously bind to non-overlapping regions of the receptor binding domain (RBD) of SARS-CoV-2 spike protein.
Dosage forms and strengths
Injection:
• tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial.
• cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial.
The dosage of EVUSHELD for use is:
• Initial dose: 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections.
• Dosing for Individuals Who Initially Received 150 mg of Tixagevimab and 150 mg Cilgavimab
For individuals who initially received 150 mg tixagevimab and 150 mg cilgavimab:
• Initial dose ≤3 months prior: 150 mg tixagevimab and 150 mg cilgavimab.
• Initial dose >3 months prior: 300 mg tixagevimab and 300 mg cilgavimab.
• Repeat dose: 300 mg of tixagevimab and 300 mg of cilgavimab every 6 months. Repeat dosing should be timed from the date of the most recent EVUSHELD dose.